The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study

Abstract

One hundred and forty one patients were treated in a combined Eastern Cooperative Oncology Group and Southwest Oncology Group phase-III study evaluating low-dose cytarabine (LDAC) versus supportive therapy for the treatment of myelodysplastic syndrome (MDS). Patients were randomized to either cytarabine 10 mg/m2 subcutaneously BID or supportive therapy… (More)
DOI: 10.1007/BF01697631

Topics

10 Figures and Tables

Cite this paper

@article{Miller1992TheEO, title={The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study}, author={Ken Miller and K. Kyungmann and Francis S. Morrison and Jane N. Winter and J. M. Bennett and Richard S Neiman and D. Head and Peter A. Cassileth and M J O'connell}, journal={Annals of Hematology}, year={1992}, volume={66}, pages={164-164} }